The level of follistatin and activin in follicular fluid of long protocol in *in vitro* fertilization

Nejla Gultekin MD

BACKGROUND: Are we estimate the success of the IVF treatment before the pregnancy test via intrafollicular hormonal markers?

OBJECTIVE: The level of follistatin and activin is measured and their levels are compared with the oocyte grade in IVF patients.

STUDY DESIGN: This study has 50 infertile patients. In our study, the best oocyte is taken from each woman. In the IVF treatment, the recombinant FSH dose around 200-300 IU. Human Chorionic Gonadotropin (HCG) 10.000 IU is administrated. The oocyte pickup is started. The level of activin and follistatin are measured with ELISA testing. The advanced oocyte morphology grading system is used and the oocytes are divided into 4 groups.

RESULTS: In my study, it is demonstrated that the worsening of quality of oocyte by declining of level of follistatin and activin in the follicular fluid. In addition, the follistatin and activin level decrease by rising of the age.

CONCLUSION: The systemic effects of gonadotropin will be more considerable reason than the fertility in the future. For this reason, we should find the available route of the local injection of gonadotropin to infertile patients. In that point, our study has an important situation in the future.

Key Words: Infertility; Follistatin; Activin; Intrafollicular Injection of the Gonadotropin; Intrafollicular Hormones
hormone (LH) and insulin like growth factor-1 (IGF-1) (28). In vitro, the activin increased the aromatase enzyme activity by induction of FSH on the granulosa cells of rats (29,30). The activin developed the ovarian follicle by decreasing of androgen production in theca cells, increasing of FSH secretion from pituitary gland and rising of insulin secretion from pancreatic β-cells (31,32). In the polycystic ovarian syndrome (PCOS), the action of activin decreased because of binding of follistatin to activin and the androgenic environment (33).

The follistatin proved as the activin binding protein and inhibitor of action of activin (34-36). For this reason, the follistatin worked as an activin regulator and has a big role in the follicle development (36-38). The follistatin has many different types (39,40), and the biochemical and physiological activity of follistatin as a 39kDa nonomerik glycoprotein (41-43). There were very little experiments about the follistatin. In the mammarian, the activin developed the ovarian follicle by 39-kDa monomerik glycoprotein (41-43). Those two different follistatin protein sequences were divided by exon 5 (44). The follistatin, with 32 kDa main protein, was small follistatin Acid (mRNA). Those two different follistatin protein sequences were divided by exon 5 (44). The follistatin, with 32 kDa main protein, was small follistatin Acid (mRNA). Those two different follistatin protein sequences were divided by exon 5 (44). The follistatin, with 32 kDa main protein, was small follistatin Acid (mRNA). Those two different follistatin protein sequences were divided by exon 5 (44). The follistatin, with 32 kDa main protein, was small follistatin Acid (mRNA). Those two different follistatin protein sequences were divided by exon 5 (44). The follistatin, with 32 kDa main protein, was small follistatin Acid (mRNA).

As a small 30-32 kDa protein, follistatin is called FS 315 (43-45). Those different structural follistatins had different activities. In the higher follistatin level, the infertility and the arrest between the first and second follicles was observed in the animal studies (46). In vitro studies, the lack of the follistatin prevented the folliculogenesis and caused the infertility (47). In the normal menstrual cycle, the midcycle rising of the follistatin was measured in contrast to polycystic ovarian syndrome (48). In vivo, the follistatin not only worked as an activin binding protein but also regulator of hormone secretion from the pituitary gland (49,52) and degraded the activin from the circulation (53,54).

In our experiment, we tried to search the effects of the amount of follistatin and activin in the follicular fluid on oocyte morphology during long protocol IVF treatment. In one research, the amount of activin A did not change during pituitary down regulation and recombinant FSH (rFSH) treatment (55). However the activin A level increased with rFSH treatment in the granulose cell culture (56). This study showed that the activin A was secreted from the granulosa cells and had the autocrine and paracrine activity. The activin rose not only aromatization but also FSH receptors on the follicle and the follicle turned to antral stage (gonadotropin dominant stage) from preantral stage and was called dominant follicle. In some researches, the level of free activin A was higher in undifferential mouse granulosa cells than the developing granulosa cells (57,58) and the lower level of activin A in follicular phase of PCOS caused the follicular arrest (59). On one study, the activin had a critical role in the oocyte maturation and was found in higher amount in the cumulus cell culture of IVF treatment (60). This study demonstrated that the activin stimulated the oocyte maturation. All of those studies emphasis the activin effect the oocyte maturation and follistatin had a role on oocyte maturation via inhibition of activin. The circulation level of activin and follistatin was measured and compared with the oocyte morphology but the follicular level was in a mystery all the time.

**MATERIALS**

- 3.75 MHz transvajinal prop (Logic 500 machine, GE, General Electric, Istanbul, Turkiye)
- Laminar flow (K system)
- Etuv
- Incubator (Heraeus BBD 6220, Germany)
- Invert microscopy (Olympus, Japan)
- Stereo microscope (Olympus, Japan)
- Microplate reader (abato, china)

**METHOD**

- This was a prospective study. This study has 52 infertile patients. The basal FSH, LH estradiol (E2) levels were measured. 2 patients quitted from the study because of "coasting". In the IVF treatment, the recombinant FSH dose was around 200-300 IU. In the folliculometre, by the measurement of the two follicles around 16.5 mm recombinant Human Chorionic Gonadotropin (HCG) 10,000 IU was administrated. After 34 h of the HCG, oocyte pickup was started. The all follicular fluids were stored at -20°C and the level of activin and follistatin were measured with Follistatin ELISA Kit and activin-A ELISA Assay kit.

**GRADING OF THE OOCYTE MORPHOLOGY**

The all oocytes were classified as germinal vesicles (GV), Meiosis I (MI), and MI (MII). The advanced oocyte grading system was used for oocytes (61).

**Advanced oocyte morphology grading system**

**GRADE 1:** The oocyte was with the clear cytoplasm or a little granulation in the cytoplasm.

**GRADE 2:** The oocyte was with the degenerated/fragmented polar body or wide perivitelline space.

**GRADE 3:** The oocyte was with the granulation in the cytoplasm or dark colored cytoplasm with the bright colored zone in the center of the oocyte.

**GRADE 4:** The degenerated oocyte was with the endocytic cytoplasmic vacuole, granulated cytoplasm, big refractile body or smooth endoplasmic reticulum which gave pronuclear appearance.

**Including criteria**

- 25-35 years old women
- Male infertility
- BMI 25 and less than 25
- Antral follicle number more than 3
- During the IVF treatment, more than 3 follicles above the 16 mm

**Excluding criteria**

- More than 35 years old women
- Infertility because of endometriosis
- Women with polycystic ovarian syndrome
- Poor prognosis; less than 3 follicles at 16 mm
- The estrogen level at HCG injection was not study criteria

**TABLE 1**

<table>
<thead>
<tr>
<th>The all informations about the groups</th>
<th>Group a (n=18)</th>
<th>Group b (n=12)</th>
<th>Group c (n=10)</th>
<th>Group d (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>The mean age (years)</td>
<td>27.39 ± 1.54*</td>
<td>28.92 ± 1.51*</td>
<td>30.9 ± 2.51*</td>
<td>33.7 ± 2.26*</td>
</tr>
<tr>
<td>FSH level in the 3.day of cycle (IU)</td>
<td>4.88 ± 1.99</td>
<td>3.8 ± 1.58</td>
<td>4.13 ± 2.13</td>
<td>5.62 ± 1.85</td>
</tr>
<tr>
<td>Estrodiaol level in the 3. day of cycle (pg/ml)</td>
<td>40.78 ± 18.75</td>
<td>53.88 ± 18.94</td>
<td>38 ± 13.99</td>
<td>44.4 ± 16.64</td>
</tr>
<tr>
<td>Antral follicle number (AFS)</td>
<td>10.22 ± 2.62</td>
<td>10.75 ± 2.86</td>
<td>9.4 ± 2.98</td>
<td>11.3 ± 3.6</td>
</tr>
<tr>
<td>Stimulation time (day)</td>
<td>8.39 ± 1.04c</td>
<td>9.17±1.9</td>
<td>10.2±1.55</td>
<td>10.5 ± 1.27</td>
</tr>
<tr>
<td>Total gonadotropin dose (IU)</td>
<td>1637.5 ± 265.44</td>
<td>1906.25 ± 451.78</td>
<td>2315 ± 533.36</td>
<td>3065 ± 363.66</td>
</tr>
<tr>
<td>The mean E2 level at HCG (pg/ml)</td>
<td>2316.44 ± 649.71</td>
<td>2302.25 ± 1025.64</td>
<td>2410.1 ± 155.54</td>
<td>2027.9 ± 559.44</td>
</tr>
<tr>
<td>The mean infertility time (years)</td>
<td>6.44 ± 0.98a</td>
<td>6.92 ± 1.68a</td>
<td>7.6 ± 2.12a</td>
<td>9.4 ± 1.26a</td>
</tr>
</tbody>
</table>

* Mann-Whitney U test, p<0.05
* Mann-whitney u test, correction with bonferroni p<0.0083 (0.05/6=0.0083)
* p<0.001

**TABLE 2**

<table>
<thead>
<tr>
<th>The results of follistatin and activin</th>
<th>Group a (n=18)</th>
<th>Group b (n=12)</th>
<th>Group c (n=10)</th>
<th>Group d (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follistatin (pg/ml)</td>
<td>4902.77 ± 439.13</td>
<td>4024.1667 ± 1017</td>
<td>3853 ± 924.60</td>
<td>3278 ± 928.76</td>
</tr>
<tr>
<td>Activin (ng/ml)</td>
<td>32.69 ± 11.94</td>
<td>32.69 ± 11.94</td>
<td>32.69 ± 11.94</td>
<td>32.69 ± 11.94</td>
</tr>
</tbody>
</table>

| J Reprod Biol Endocrinol Vol 1 No 1 Winter 2017 | 13 |
RESULTS
In our study, the best oocyte was taken from each woman and 50 oocytes were gathered. The advanced oocyte morphology grading system was used and the oocytes were divided into 4 groups; group a: the oocyte morphology was grade 1, group b: the oocyte morphology was grade 2, group c: the oocyte morphology was grade 3 and group d: the oocyte morphology was grade 4. There was 18 oocytes in the group a; 12 oocytes in group b; 10 oocytes in the group c and 10 oocytes in the group d. The mean age in the group a was 27.39 ± 1.54; in group b was 28.92 ± 1.51; in group c was 30.9 ± 2.51; in group d was 33.7 ± 2.26. The women in the group a were more younger than the women in the group c and d (p=0.0001, Mann-Whitney U test) and the women in the group b were younger than the group d (p=0.0001, Mann-Whitney U test) (Table 1 & 2).

In the study, the infertility duration was compared and the mean time of infertility was 4.44 ± 0.98 years in the group a; 6.92 ± 1.68 years in the group b; 7.6 ± 2.12 years in the group c; 9.4 ± 1.26 years in the group d. The duration of infertility in the group a was shorter than the other groups statistically (p=0.0001, Mann-Whitney U test).

In our study, we compared the gonadotropin treatment time; the mean time of the gonadotropin treatment was 8.39 ± 1.04 days in group a; 9.17 ± 1.19 days in group b; 10.2 ± 1.55 days in group c; 10.5 ± 1.27 days in group d. The mean stimulation time in the group a was less than the in group d (p=0.0001, Mann-Whitney U test).

The statistical importance was found between group a and group b (p=0.0001, Mann-Whitney U test); between group a and group c (p=0.012, Mann-Whitney U test) and between group a and group d (p=0.0001, Mann-Whitney U test).

The antral follicle numbers were compared. The mean antral follicle numbers were 10.22 ± 2.62 in group a; 10.75 ± 2.86 in group b; 9.4 ± 2.98 in group c; 11.3 ± 3.6 in group d. There was no statistical importance between groups.

The mean follicular fluid FSH level in the 3rd day of the cycle before IVF treatment was compared. The mean FSH level in the beginning was 4.88 ± 1.99 IU/L in the group a; 3.8 ± 1.58 IU/L in the group b; 4.13 ± 2.13 IU/L in the group c; 5.62 ± 1.85 IU/L in the group d. There was no statistical importance between groups.

The serum estradiol levels at the HCG application was measured and compared between groups. The maximum level of the estrogen at the HCG day (Graph 7). The rising of mean intrafollicular follistatin level increased the activin level (Graph 6). The mean intrafollicular follistatin level increased with the serum estradiol level at HCG day (Graph 5).

The level of FSH in the 3rd day of the menstrual cycle. The mean FSH level in the beginning was 40.78 ± 18.75 ng/ml in group a; 53.88 ± 18.94 ng/ml in group b; 38 ± 13.99 ng/ml in group c; 44.44 ± 16.4 ng/ml in group d. There was no statistical importance between groups.

The total recombinant FSH doses were compared and the mean total recombinant FSH (rFSH) dose was 1637.5 ± 265.44 IU in group a; 1906.25 ± 451.78 IU in group b; 2315 ± 533.36 IU in group c; 3065 ± 363.66 IU in group d. The total rFSH dose was lower in group a than group c and d (p=0.0001, Mann-Whitney U test). In the group b, the rFSH dose was lower than the group d (p=0.0001, Mann-Whitney U test). In the group c, the rFSH dose is higher than the group d (p=0.001, Mann-Whitney U test).

At the oocyte pick up, the level of follistatin and activin were measured in the follicular fluid. The mean follistatin level of follicular fluid in the group a was 4902.77 ± 439.13 pg/ml; 4024.1667 ± 1017 pg/ml in group b; 3853 ± 924.60 pg/ml in group c; 3278 ± 928.76 pg/ml in group d. The level of follistatin in the follicular fluid was higher in group a than the other groups. The statistical importance was found between group a and group b (P=0.033, Mann-Whitney U test); between group a and group c (p=0.001, Mann-Whitney U test); between group a and group d (p=0.0001, Mann-Whitney U test).

The activin level in the follicular fluid was measured and compared in the groups. The mean activin level in the group a is 32.69 ± 11.94 ng/ml; 9.22 ± 3.15 ng/ml in group b; 5.26 ± 1.85 ng/ml in group c; 2.32 ± 0.79 ng/ml in group d. The mean activin measurement in group a was statistically higher than other groups. The statistically importance was found between group a and group b (p=0.0001, Mann-Whitney U test); group a and group c (p=0.0001, Mann-Whitney U test); group a and group d (p=0.0001, Mann-Whitney U test).

The distribution of the activin and follistatin level in Graphs 1 and 2.

The rising of mean intrafollicular follistatin level increased the activin level at HCG day (Graph 7).
During the folliculogenesis, the autocrine-paracrine and the endocrine factors worked in a rule for mature oocyte that had fertility capacity. The oocyte maturation depend on the granulosa cells and the follicle development depend on the oocytes (62). The follicular growing and oocyte maturation were a complicated process that were connected to each other. The human follicular fluid analysis explained the effect of the granulosa cells on the oocyte development and maturation. In vitro studies, the nuclear maturation of the oocyte and formation of the oocyte cumulus complex were affected from activin and follistatin (63,64).

Activin had an important role on the granulosa cells for differentiation and the follicular growing. In some studies, the activin re-aggregated the granulosa cells (27,65,66) by increasing of aromatase activity which was induced by FSH, by rising of FSH receptors on the granulosa cells and by binding to activin receptors directly (67). So that, activin induced the steroidogenesis, increased the estrogen and progesteron production, follicular development and oocyte maturation with FSH (27). The effect of the activin on the follicle was done by binding of the activin to activin receptors on the granulosa cells oocytes (27,68). Although the positive effect of activin on the oocyte maturation, the mechanism on oocyte morphology was not clearly demonstrated. Lau et al. found positive relation between cumulus cells, activin, oocyte morphology and embryo (60).

On the other study, the level of intrafollicular follistatin was higher in the MI ve MI oocytes at ovarian stimulation (69). For this reason, the follistatin had responsibility on oocyte quality and oocyte maturation. In the other study, the level of follistatin in the follicular fluid was higher in the MI ve MI oocytes (69). The follistatin had a role on the oocyte grade and it was necessary for the oocyte maturation. In the one study, the relation between m-RNA level of the activin and follistatin level in the follicular fluid and oocyte maturation, fertilization capacity and embryo grade was searched (70). As a result, the level of the follistatin and activin directly affected the oocyte and embryo quality. In vitro study with the mouse showed that the folliculogenesis was paused and the infertility was appeared by the lack of follistatin (47). In our study, the follistatin was found in a higher amount at the follicular fluid of the grade 1 oocytes than the grade 2-4 oocytes but not statistically importance.

The follistatin was an activin binding protein so that it inhibited the activin (71). The activin A level in the oocyte cumulus complex was higher in the culture of the oocyte complex medium (72). The comparing of circulation level of the follistatin in the different age groups in the follicular phase showed the higher level of circulating follistatin among the young age groups (mean age was 23 years) than the perimenopause (mean age was 49 years) (73). In our study, we find the decreasing level of follistatin and activin in the follicular fluid of rFSH using women by the increasing of the age.

The oocyte quality was studied in different IVF cases and the results show the basal FSH, estradiol and antral follicle did not affect the oocyte quality (74-78). The basal estradiol in low or high level canceled the IVF success. On the other hand, the basal FSH level showed the ovarian reserve and decreased IVF success and the cancelling of the cycle (75). The basal antral follicle number 4 or less decreased the ovarian response to IVF treatment, caused the canceling and declining of the pregnancy rate (76). The pregnancy rate was higher in the women less than 35 ages than above 40 ages with normal FSH/E2 level and the success of IVF was not related with the FSH level but was related with age (77). In our study we demonstrated also the worsen of oocyte quality with the increasing of the rFSH doses and rising of age. However, we did not find any differences between basal FSH, estradiol, antral follicle number and the estradiol level in HCG injection day because those parameters were related with the oocyte reserve and they didn’t have relation with the oocyte grade (4,6,8,73). As we seen in our study, the age was more powerful factor on the oocyte quality. We studied the follistatin and activin levels in follicular fluid with grading of oocyte quality and we demonstrated the worsening of quality of oocyte by declining of level of follistatin and activin and increasing of the age, not statistically. In other studies, the intrafollicular follistatin level in MI and M oocyte containing follicles was higher in IVF treatment (69) and the activin A level was higher in good quality oocyte cultures in rFSH usage (72). In our study, the follistatin and activin levels were higher in the good quality oocytes in contrast to worse quality oocytes, not statistically. In addition, the follistatin and activin levels decreased by rising of the age. For this reason, our study figured out that the intrafollicular follistatin and activin levels declined by rising of the age and their low levels had negative effects on the oocyte grade.

**SUMMARY**

This was a prospective study. We compared the level of follistatin and activin A level in the follicular fluid with the oocyte morphology in the long protocol treatment in the IVF and we determined that the follistatin and
The level of follistatin and activin

activin A level were higher in the good oocyte morphology. This study was done on limited patients because of financial reasons. For understanding the intrafollicular hormonal changes on the oocyte morphology, this study should be done on more patients. The understanding of the intrafollicular physiology in IVF treatment will provide better treatment options in poor responders and may change the treatment procedures such as applying less amount of gonadotropin directly to follicular fluid. So that the systemic effect of gonadotropin will be bypassed and successful IVF cycle can be done in minimal doses of gonadotropin even if poor responders.

CONCLUSION

The follistatin and activin were proteins that worked on the oocyte quality and maturation. They could be found in the circulation and in the specific parts of the human body. They seem to be counteracted each other but this study showed that they acted together in some amount and they inhibited each other in some levels during oocyte maturation. The importance of those proteins in the oocyte grade was demonstrated. Although the statistically results couldn’t be documented, the study should be reviewed or designed in a large patients group and or in the antagonist protocols.

REFERENCES


